ArticleBlood cancer journal2025

Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma.

Tara Sebastian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.